Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

PURPOSE: Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF). The objectives of this analysis were to develop a population pharmacokinetic (PK) model to characterize fedratin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Ken, Zhou, Simon, Krishna, Gopal, Palmisano, Maria, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768916/
https://www.ncbi.nlm.nih.gov/pubmed/31444617
http://dx.doi.org/10.1007/s00280-019-03929-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768916/
https://www.ncbi.nlm.nih.gov/pubmed/31444617
http://dx.doi.org/10.1007/s00280-019-03929-9

Ejemplares similares